Designing Novel InhA Inhibitors for Antituberculosis Agents Using ab Initio Fragment Molecular Orbital Calculations

利用从头算片段分子轨道计算设计新型抗结核药物InhA抑制剂

阅读:1

Abstract

Tuberculosis is an ancient chronic disease caused by Mycobacterium tuberculosis (M. tuberculosis) and remains one of the leading causes of death worldwide. InhA, an enoyl-ACP reductase in M. tuberculosis, plays a crucial role in the biosynthesis of mycolic acids, essential constituents of the mycobacterial cell wall. Therefore, InhA enzyme has been considered as a promising target for the development of novel antitubercular drugs. In our previous molecular simulations, we investigated the interactions between InhA and a series of benzimidazole derivatives for the crystal structure of InhA (PDB ID: 6R9W) using ab initio fragment molecular orbital (FMO) calculations. To design highly effective benzimidazole derivatives as InhA inhibitors, we here extended our molecular simulations to other derivatives and highlighted key electronic-level interactions between InhA and these compounds. Indeed, we strategically modified substituents at three sites of the 2,3-dihydro-1H-indene ring of the most potent benzimidazole derivative, with the aim of facilitating hydrogen bond formation to InhA residues. A total of 24 compounds were rationally designed and virtually screened based on Lipinski's rule of five and toxicity predictions, ultimately obtaining nine promising candidate compounds. Using FMO calculations, specific interactions were elucidated between InhA and the compounds to highlight key interactions for achieving high binding affinity to InhA. Notably, the highest-affinity inhibitor exhibited strong hydrogen bond interactions with the backbones of Gln100, Ala157, and Ile215, as well as nicotinamide adenine dinucleotide of InhA. These findings provide valuable structural insights for designing novel benzimidazole derivatives with improved binding efficiency to InhA. Overall, our ab initio molecular simulations provide crucial insights for the rational design of more effective InhA inhibitors, potentially advancing tuberculosis chemotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。